Neurimmune Appoints John Dellapa as General Counsel

Neurimmune logo

SCHLIEREN / ZURICH, Switzerland, March 01, 2019 / B3C newswire / -- Neurimmune today announced the appointment of John Dellapa as General Counsel. John joins Neurimmune from the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, an AmLaw 100 law firm widely recognized for its outstanding life sciences practice. As a corporate transactional lawyer with more than 30 years of experience in the life science industry, John has advised Neurimmune on numerous global transactions since Neurimmune’s inception in 2006.

“At Neurimmune, we wholeheartedly welcome John Dellapa in his new role as General Counsel", said Roger Nitsch, Neurimmune’s CEO & President. "In his prior function as Neurimmune's external counsel, John accompanied our transformation into a well-funded, Phase III stage company by crafting sustainable alliances with pharma and large biotech companies. John’s wealth of legal and executive experience will be instrumental in further advancing Neurimmune as we continue our efforts to develop therapies against diseases that severely impact daily life.”

John Dellapa is a board member of the BioBuilder Educational Foundation and a member of the Licensing Executives Society. Prior to joining Mintz Levin, John served for 9 years as group general counsel at Fisher Scientific International, Inc. John holds a Juris Doctor degree from George Washington University and Bachelor’s degree in management from Boston College. He will be located at Neurimmune’s headquarters in Schlieren, Switzerland.

 

About Neurimmune
Neurimmune is a Swiss clinical stage biotech company translating human immune memory into game changing therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes and progressive multifocal leukoencephalopathy, with potential therapies in advanced preclinical stages.

 

Contact

Neurimmune
Fabian Buller
Chief Business Officer
+41 44 755 46 46
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Published by B3C newswire and shared through Newronic®

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok